These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 17035667)

  • 41. Structure-activity relationships of Bak derived peptides: affinity and specificity modulations by amino acid replacement.
    Frey V; Viaud J; Subra G; Cauquil N; Guichou JF; Casara P; Grassy G; Chavanieu A
    Eur J Med Chem; 2008 May; 43(5):966-72. PubMed ID: 17692431
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Design, synthesis, and biological evaluation of potent c-Met inhibitors.
    D'Angelo ND; Bellon SF; Booker SK; Cheng Y; Coxon A; Dominguez C; Fellows I; Hoffman D; Hungate R; Kaplan-Lefko P; Lee MR; Li C; Liu L; Rainbeau E; Reider PJ; Rex K; Siegmund A; Sun Y; Tasker AS; Xi N; Xu S; Yang Y; Zhang Y; Burgess TL; Dussault I; Kim TS
    J Med Chem; 2008 Sep; 51(18):5766-79. PubMed ID: 18763753
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Rapid evolution of 6-phenylpurine inhibitors of protein kinase B through structure-based design.
    Donald A; McHardy T; Rowlands MG; Hunter LJ; Davies TG; Berdini V; Boyle RG; Aherne GW; Garrett MD; Collins I
    J Med Chem; 2007 May; 50(10):2289-92. PubMed ID: 17451235
    [TBL] [Abstract][Full Text] [Related]  

  • 44. N-(thiazol-2-yl)-2-thiophene carboxamide derivatives as Abl inhibitors identified by a pharmacophore-based database screening of commercially available compounds.
    Manetti F; Falchi F; Crespan E; Schenone S; Maga G; Botta M
    Bioorg Med Chem Lett; 2008 Aug; 18(15):4328-31. PubMed ID: 18621522
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Apoptosis in leukemia: from molecular pathways to targeted therapies.
    Schimmer AD
    Best Pract Res Clin Haematol; 2008 Mar; 21(1):5-11. PubMed ID: 18342807
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Development of novel G-protein-coupled receptor 54 agonists with resistance to degradation by matrix metalloproteinase.
    Tomita K; Oishi S; Ohno H; Peiper SC; Fujii N
    J Med Chem; 2008 Dec; 51(23):7645-9. PubMed ID: 19007202
    [TBL] [Abstract][Full Text] [Related]  

  • 47. From purified GPCRs to drug discovery: the promise of protein-based methodologies.
    Alkhalfioui F; Magnin T; Wagner R
    Curr Opin Pharmacol; 2009 Oct; 9(5):629-35. PubMed ID: 19443270
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Design and implementation of an ribonucleic acid (RNA) directed fragment library.
    Bodoor K; Boyapati V; Gopu V; Boisdore M; Allam K; Miller J; Treleaven WD; Weldeghiorghis T; Aboul-ela F
    J Med Chem; 2009 Jun; 52(12):3753-61. PubMed ID: 19445516
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Modulation of biomolecular interactions with complex-binding small molecules.
    Cai Z; Greene MI; Berezov A
    Methods; 2008 Sep; 46(1):39-46. PubMed ID: 18571508
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Solid-state NMR spectroscopy as a tool for drug design: from membrane-embedded targets to amyloid fibrils.
    Middleton DA
    Biochem Soc Trans; 2007 Nov; 35(Pt 5):985-90. PubMed ID: 17956260
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Structure-based design of molecular cancer therapeutics.
    van Montfort RL; Workman P
    Trends Biotechnol; 2009 May; 27(5):315-28. PubMed ID: 19339067
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Recent progress in fragment-based lead discovery.
    Schulz MN; Hubbard RE
    Curr Opin Pharmacol; 2009 Oct; 9(5):615-21. PubMed ID: 19477685
    [TBL] [Abstract][Full Text] [Related]  

  • 53. NMR structure determination of protein-ligand complexes by lanthanide labeling.
    Pintacuda G; John M; Su XC; Otting G
    Acc Chem Res; 2007 Mar; 40(3):206-12. PubMed ID: 17370992
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Structure of the BH3 domains from the p53-inducible BH3-only proteins Noxa and Puma in complex with Mcl-1.
    Day CL; Smits C; Fan FC; Lee EF; Fairlie WD; Hinds MG
    J Mol Biol; 2008 Jul; 380(5):958-71. PubMed ID: 18589438
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Structure-activity relationships of phenylalkylamines as agonist ligands for 5-HT(2A) receptors.
    Blaazer AR; Smid P; Kruse CG
    ChemMedChem; 2008 Sep; 3(9):1299-309. PubMed ID: 18666267
    [TBL] [Abstract][Full Text] [Related]  

  • 57. NMR-guided fragment-based approach for the design of AAC(6')-Ib ligands.
    Lombès T; Bégis G; Maurice F; Turcaud S; Lecourt T; Dardel F; Micouin L
    Chembiochem; 2008 Jun; 9(9):1368-71. PubMed ID: 18464231
    [No Abstract]   [Full Text] [Related]  

  • 58. Conformational and dynamics changes induced by bile acids binding to chicken liver bile acid binding protein.
    Eberini I; Guerini Rocco A; Ientile AR; Baptista AM; Gianazza E; Tomaselli S; Molinari H; Ragona L
    Proteins; 2008 Jun; 71(4):1889-98. PubMed ID: 18175325
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Novel soluble myeloid cell leukemia sequence 1 (Mcl-1) inhibitor (E,E)-2-(benzylaminocarbonyl)-3-styrylacrylonitrile (4g) developed using a fragment-based approach.
    Zhang Z; Song T; Li X; Wu Z; Feng Y; Xie F; Liu C; Qin J; Chen H
    Eur J Med Chem; 2013 Jan; 59():141-9. PubMed ID: 23220642
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A novel approach for characterizing protein ligand complexes: molecular basis for specificity of small-molecule Bcl-2 inhibitors.
    Lugovskoy AA; Degterev AI; Fahmy AF; Zhou P; Gross JD; Yuan J; Wagner G
    J Am Chem Soc; 2002 Feb; 124(7):1234-40. PubMed ID: 11841292
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.